M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Phase 1

Withdrawn

Conditions: Umbilical Cord Blood Transplant

Interventions: Drug: CYT107

First Posted Date: 2018-07-26

Last Posted Date: 2019-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03600896

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Phase 1

Active, not recruiting

Conditions: Recurrent Osteosarcoma
Refractory Osteosarcoma

Interventions: Drug: Docetaxel
Drug: Gemcitabine
Drug: Hydroxychloroquine

First Posted Date: 2018-07-26

Last Posted Date: 2025-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT03598595

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor

Phase 2

Active, not recruiting

Conditions: Oligometastatic Malignant Solid Neoplasm

Interventions: Other: Best Practice
Procedure: Local Consolidation Therapy

First Posted Date: 2018-07-26

Last Posted Date: 2025-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 380

Registration Number: NCT03599765

Locations: 🇺🇸
Community Health Center, Coldwater, Michigan, United States
🇺🇸
Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸
OhioHealth Mansfield Hospital, Mansfield, Ohio, United States

and more 9 locations

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2018-07-26

Last Posted Date: 2025-03-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT03600155

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Phase 2

Active, not recruiting

Conditions: Stage IV Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Colorectal Carcinoma Metastatic in the Lung
Stage IVA Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Colorectal Adenocarcinoma

Interventions: Procedure: Metastasectomy
Drug: Chemotherapy

First Posted Date: 2018-07-26

Last Posted Date: 2025-01-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT03599752

Locations: 🇨🇦
University of Montreal, Montreal, Quebec, Canada
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇨🇦
University Health Network Princess Margaret Cancer Center P2C, Toronto, Ontario, Canada

and more 3 locations

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

Early Phase 1

Recruiting

Conditions: Rectal Adenocarcinoma
Stage II Rectal Cancer AJCC v8
Stage IIA Rectal Cancer AJCC v8
Stage IIB Rectal Cancer AJCC v8
Stage IIC Rectal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8
Stage IIIA Rectal Cancer AJCC v8
Stage IIIB Rectal Cancer AJCC v8
Stage IIIC Rectal Cancer AJCC v8

Interventions: Other: Questionnaire Administration
Drug: Chemotherapy
Other: Patient Observation
Procedure: Resection of Rectum

First Posted Date: 2018-07-20

Last Posted Date: 2025-05-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT03594630

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rectal Administration of Opioids Using the Macy Catheter in Reducing Pain in Patients With Advanced Cancer

Not Applicable

Withdrawn

Conditions: Pain
Advanced Malignant Neoplasm

Interventions: Device: Macy Catheter
Procedure: Pain Therapy
Other: Questionnaire Administration
Other: Survey Administration

First Posted Date: 2018-07-19

Last Posted Date: 2020-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03592459

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Myeloproliferative Neoplasm
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
High Risk Myelodysplastic Syndrome
Myeloid Sarcoma
Philadelphia Chromosome Positive

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Dexrazoxane Hydrochloride
Drug: Gemtuzumab Ozogamicin
Drug: Idarubicin

First Posted Date: 2018-07-18

Last Posted Date: 2025-06-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03589729

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer

Phase 2

Active, not recruiting

Conditions: SMARCB1 Negative
Stage IV Renal Cell Cancer AJCC V8
Metastatic Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC V8
Metastatic Kidney Medullary Carcinoma

Interventions: Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Gemcitabine
Drug: Gemcitabine Hydrochloride
Drug: Ixazomib
Drug: Ixazomib Citrate

First Posted Date: 2018-07-16

Last Posted Date: 2025-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03587662

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Active, not recruiting

Conditions: Deleterious BRCA1 Gene Mutation
Deleterious BRCA2 Gene Mutation
Endometrial Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Endometrial Carcinoma
High Grade Ovarian Serous Adenocarcinoma
Progressive Disease
Platinum-Resistant Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Drug: Copanlisib
Drug: Niraparib

First Posted Date: 2018-07-13

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT03586661

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy